Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030. However, at present, the diagnosis rate and treatment rate of chronic HBV and HCV in China are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face.
This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.
Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. According to the survey, there are about 93 million chronic HBV infected people and 10 million chronic HCV infected people in China, accounting for 36.19% and 14.08% of the global HBV and HCV infected people respectively. Chronic HBV and HCV infection is the main cause of liver cirrhosis and liver cancer, which places a great burden on the national economy.
In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030, including 90% diagnosis rate, 80% treatment rate and 90% cure rate of viral hepatitis, in order to reduce 65% of viral hepatitis related deaths and reduce the disease burden. However, at present, the diagnosis rate of chronic HBV in China is 18.7%, the treatment rate is 10.8%, the diagnosis rate of chronic HCV is 30%, and the treatment rate is 9%, which are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face.
This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hepatitis B cohort |
|
| |
| Hepatitis C cohort |
|
| |
| Cirrhosis cohort |
|
| |
| Liver cancer cohort |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anti-virus treatment | Other | Anti-virus treatment |
|
| Measure | Description | Time Frame |
|---|---|---|
| Epidemiological characteristics of hepatitis B and C | Epidemiological characteristics of hepatitis B and C in Danzhou City, Hainan Province | up to 192 weeks |
| Long-term outcome | Long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks |
| Risk factors | Risk factors for long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of cirrhosis | Incidence of cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks |
| Incidence of liver cancer | ncidence of liver cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Hepatitis B or hepatitis C patients will be enrolled in this study.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Junfeng Chen, Dr. | Contact | 86-20-85252363 | mountainchen@139.com |
| Name | Affiliation | Role |
|---|---|---|
| Bingliang Lin, Dr. | Sun Yat-sen University | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | 1.Lu FM, Zhuang H. Management of hepatitis B in China[J]. Chin Med J ( Engl) , 2009, 122(1): 3-4． 2.Chen YS, Li L, Cui FQ et al. Seroepidemiological study of hepatitis C in China[J].Chinese Journal of Epidemiology, 2011, 32:888-891. 3.Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6): 2099 -2108． 4.Huang YW, Yang SS, Fu SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study[J]. Patology, 2014,60:807-814. 5.69th World Health Assembly. Draft Global Health Sector Strategies. April 2016. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1 (accessed February 2017) 6.Global Hepatitis Report, 2017. http://www.who.int/mediacentre/factsheets/fs164/zh. 7.CDA Foundation's Polaris Observatory; 2020 Available from https://cdafound.org/polaris/ (Accessed 2020-06-09). |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples will be retained at each timepoints.
| up to 192 weeks |
| Hepatic decompensation | Hepatic decompensation rate for HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks |
| Survival rate for liver cancer | Survival rate for liver cancer patients in Danzhou City, Hainan Province | up to 192 weeks |
| Survival rate for cirrhosis | Survival rate for cirrhosis patients in Danzhou City, Hainan Province | up to 192 weeks |
| HBV interruption rate of perinatal transmission | HBV interruption rate of perinatal transmission in Danzhou City, Hainan Province | up to 192 weeks |
| HBsAg loss | The HBsAg loss rate of HBV infected patients in Danzhou City, Hainan Province | up to 192 weeks |
| D004266 |
| DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |